Procurement Summary
Country : USA
Summary : RFI Novel Antimalarial Drug Targets
Deadline : 19 May 2025
Other Information
Notice Type : Tender
TOT Ref.No.: 118808425
Document Ref. No. : PANDHA-25-P-0000-015601-RFI-Novel-Antimalarial-Drug-Targets
Financier : Self Financed
Purchaser Ownership : Public
Tender Value : Refer Document
Purchaser's Detail
Name :Login to see tender_details
Address : Login to see tender_details
Email : Login to see tender_details
Login to see detailsTender Details
Description
This Request for Information (RFI)/Sources Sought (SS) Notice is for market research information and planning purposes only, and shall not be construed as a solicitation or as an obligation on the part of WRAIR, CIDR, VDB, or the Defense Health Agency (DHA) US Army Medical Research Acquisition Activity (USAMRAA).
This non-commercial R&D requirement is expected to be a two-year study with a straight two-year Period of Performance (PoP) beginning September 30, 2025, and ending September 29, 2027.
The work to be performed under this contract shall be performed off-site at Contractor facilities that may be located anywhere in the Continental United States (CONUS).
See attached Request for information With DRAFT Statement of Work.
Active Contract Opportunity
Notice ID : PANDHA-25-P-0000-015601-RFI-Novel-Antimalarial-Drug-Targets
Related Notice
Department/Ind. Agency : DEPT OF DEFENSE
Sub-tier : DEFENSE HEALTH AGENCY (DHA)
Office: ARMY MED RES ACQ ACTIVITY
General Information
Contract Opportunity Type: Sources Sought (Original)
Original Published Date: May 07, 2025 03:05 pm EDT
Original Response Date: May 19, 2025 10:00 am EDT
Inactive Policy: 15 days after response date
Original Inactive Date: Jun 03, 2025
Initiative: None
Classification
Original Set Aside:
Product Service Code: AN13 - HEALTH R&D SERVICES; HEALTH CARE SERVICES; ExPERIMENTAL DEVELOPMENT
NAICS Code: 541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Place of Performance: USA
Documents
Tender Notice
A03-Request-for-Information.pdf